Медикаментозная терапия стабильного течения хронической обструктивной болезни легких

1. Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких: Федеральная программа: Практическое руководство для врачей. 2-е изд. М.; 2004.

2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2007 (www.goldcopd.com).

3. Britton J., Knox A. Helping people to stop smoking: the new smoking cessation guidelines. Thorax 1999; 54: 1–2.

4. Чучалин А.Г., Сахарова Г.М., Новиков К.Ю. Практическое руководство по лечению табачной зависимости. М.; 2001.

5. Samet J., Utell M.J. Ambient air pollution. In: Rosenstock L., Cullen M., eds. Textbook of occupational and environmental medicine. Philadelphia: WB Saunders Co; 1994. 53–60.

6. Nichol K.L., Margolis K.L., Wuorenma J. et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 1994; 331: 778–784.

7. Cotton M.M., Bucknall C.E., Dagg K.D. et al. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Thorax 2000; 55: 902–906.

8. Siafakas N.M., Vermeire P. Pride N.B. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. J. 1995; 8: 1398–1420.

9. Rennard S.I., Serby C.W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62–70.

10. Own L.S., Boonyongsunchai P., Webb S. et al. Function of pulmonary Neuronal M? Muscarinic receptors in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1320–1325.

11. Dusser D., Bravo M L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547–555.

12. Powrie D.J., Wilkinson T.M.A., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Respir. J. 2007; 30: 472–478.

13. O'Donnell D.E., Fluge T., Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur. Respir. J. 2004; 24: 86–94.

14. Halpin D.M.G. Number needed to treat as a measure of treatment effect. Proceeding ATS 2007. San Francisco, May 18–23, 2007.

15. Mahler D.A., Donohue J.E., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–965.

16. Dahl R., Greefhorst L.A., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778–784.

17. Rossi A., Kristufec K., Levine B.E. et al. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058–1069.

18. van Noord J.A., Aumann J L. Comparison of tiotropium once daily,formoterol twice daily and both combined jnce daily in patients with COPD. Eur. Respir. J. 2005; 26: 214–222.

19. Di Marco F., Verga M., Santus P. et al. Effects of formoterol, tiotropium and there combination in the treatment of exacerbation COPD. Respir. Med. 2006; 100: 1925–1932.

20. Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2000; www.update-software.com.

21. Sutherland E.R., Crapo J.D., Bowler R.P. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. J. Chron. Obstruct. Pulm. Dis. 2006; 3: 195–202.

22. Decramer M., Rutten van Molken M. Dekhuijzen P.N. et al. Effect of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552–1560.

23. Grandjean E.M., Berthet P., Ruffmann R. et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22: 209–221.

24. Management of COPD in adults in primary and secondary care. NICE Guideline-Chronic Obstructive Pulmonary Disease. Thorax 2004; 59 (suppl.): 1–232.

25. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819–1823.

26. Pauwels R.A., Lofdahl C.G., Laitinen L. A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948–1953.

27. Burge P.S., Calverley P.M., Jones P.W. et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.

28. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.

29. Calverley P.M., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449–56.

30. Jones P.W., Willitis L.R., Burge P.S. et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (1): 68–73.

31. van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166 (10): 1358–1363.

32. Tkacova R., Toth S., Sin D.D. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir. Med. 2006; 100: 385–392.

33. Calverley P.M. Pharmacotherapy can prevent exacerbations of COPD. Proceeding ATS 2007. San Francisco, May 18–23, 2007.

34. Leigh R., Pizzichini M.M.M., Morris M.M. et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27: 964–971.

35. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.

36. Calverley P.M., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449–56.

37. Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007. V. 22. № 356(8). Р. 775–789.

38. Wilt T.J., Bloomfield H.E., MacDonald R. et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004; 164: 1427–1436.

39. D'Amato M., Ando F., Santus P.P. et al. Clinical effects of adding fluticasone propionate/salmeterol and tiotropium in severe-to-very severe. Eur. Respir. J. 2005; 26 (suppl. 49): s14.

40. Aaron S.D., Vandemheem K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. An. Intern. Med. 2007; 146: 545–556.

41. Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19–26.

42. Сelli B.R., MacNee W., and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS-position paper. Eur. Respir. J. 2004; 23 (6): 932–946.

43. Burge P.S., Calverley P.M., Jones P.W. et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58 (8): 654–658.